Loading
CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.
Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-induced necroptosis. Negatively regulates NF-kappa-B activation by deubiquitinating upstream signalling factors. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation.
Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.98, animal model 0.44, genetic association 0.02, somatic mutation 0.94). IntOGen calls it a driver in 11 cohorts (2 activating, 7 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non-Small Cell Lung Cancer and others.
In plain words · CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.
CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.
Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-induced necroptosis.
No product in this corpus aims at CYLD yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
First described 1998. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 1998, "Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:2584 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NQC7 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000083799 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: melanoma 0.58, skin cancer 0.57, thymic carcinoma 0.51 (GraphQL API, CC0)); IntOGen CYLD (driver in 11 cohorts (Act 2, LoF 7); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-induced necroptosis. Negatively regulates NF-kappa-B activation by deubiquitinating upstream signalling factors. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signalling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilisation of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarisation, cell migration, and angiogenesis. Location: Cytoplasm; Cytoplasm, perinuclear region; Cytoplasm, cytoskeleton; Cell membrane (UniProt). Locus 16q12.1 (HGNC).
Query for this target: (TITLE:"CYLD" OR ABSTRACT:"CYLD" OR TITLE:"CYLD lysine 63 deubiquitinase" OR ABSTRACT:"CYLD lysine 63 deubiquitinase" OR TITLE:"Ubiquitin carboxyl-terminal hydrolase CYLD" OR ABSTRACT:"Ubiquitin carboxyl-terminal hydrolase CYLD" OR TITLE:"KIAA0849" OR ABSTRACT:"KIAA0849" OR TITLE:"USPL2" OR ABSTRACT:"USPL2" OR TITLE:"CYLD1" OR ABSTRACT:"CYLD1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CYLD, not a curated reading list.
Shares Nasopharyngeal carcinoma, IntOGen, Breast cancer (all types), Open Targets Platform.
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, IntOGen, Head and neck squamous cell carcinoma.
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, IntOGen, Head and neck squamous cell carcinoma.
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, IntOGen, Breast cancer (all types).
Shares Nasopharyngeal carcinoma, IntOGen, Head and neck squamous cell carcinoma, Breast cancer (all types).
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, IntOGen.